Bristol Myers Squibb announced that the FDA has accepted the supplemental Biologics License Application for Opdivo plus chemotherapy for the neoadjuvant treatment of patients with resectable non-small cell lung cancer.
[Bristol Myers Squibb]
Sorry, but the selected Zotpress account can't be found.